Opthea (ASX:OPT) returns from suspension with A$31.2m and a pivot to lung disease

The failed wet AMD program is gone, replaced by a smaller, cheaper rare lung disease bet

Opthea (ASX:OPT) is back on the boards from today (3 June 2026), ending a long trading suspension and reintroducing itself as a very different company to the one it was when shares last traded in March 2025. The wet AMD ambition that defined Opthea for years is gone. In its place sits a focused rare disease program targeting lymphangioleiomyomatosis, or LAM, a chronic lung disease that primarily affects women and currently has no approved therapy directly targeting its underlying biology.

The pivot is built around OPT-302, the same VEGF-C and VEGF-D inhibitor that failed in late-stage wet AMD trials. The science that did not work in the eye may have a credible second life in the lung, where elevated VEGF-C and VEGF-D are central to how LAM progresses.

Opthea is reinstating with A$31.2 million in cash as at 31 March 2026, an 18-month runway, a three-person board led by Executive Chair Dr Jeremy Levin, and a proposed name change to Ceryvyn Therapeutics. The story is no longer about a blockbuster eye drug. It is about whether a stripped-down biotech can stage-gate its way through preclinical work, early human data and proof-of-concept on roughly A$13.1 million of planned spend.

Why LAM actually fits the OPT-302 mechanism better than you’d expect

LAM is driven by abnormal VEGF-C and VEGF-D signalling through VEGFR-3, the exact pathway OPT-302 was designed to block. The current standard of care is an immunosuppressant that does not target this biology directly, often comes with systemic side effects, and is frequently discontinued by patients.

That sets up a cleaner therapeutic rationale than Opthea ever had in wet AMD, where it was layering on top of established anti-VEGF-A drugs. Here, the mechanism is the disease. Whether it translates clinically is another question, but the biological case is the strongest part of the relaunch.

The plan is to nebulise OPT-302 so it reaches the lungs directly, which is where the clinical burden of LAM concentrates. That formulation work is currently the gating item in Stage 1.

The A$13.1m budget tells you exactly how lean this version of Opthea is

The disclosed use of funds shows roughly A$6.0 million going to the LAM program itself over 18 months, with the rest absorbed by corporate, administration, consultants and director fees. That is a tiny clinical budget by biotech standards, and it reflects an outsourced model where third-party service providers do most of the work.

The capital efficiency cuts both ways. It buys Opthea time and reduces the dilution pressure that would otherwise hang over a fresh listing, but it also means the program advances slowly and on a tight margin for error. The board has structured progression between Stages 1, 2 and 3 as conditional on data, which is the right call but also signals how much can still go wrong.

The budget runs to roughly the end of September 2027 and a capital raise is not in the near-term picture. Stage 3 clinical work, if it happens at all, is almost certainly funded from a future round.

Orphan drug status is where the commercial logic actually lives

LAM is rare enough to qualify for orphan drug designation in the US, EU, Japan and Australia, which can deliver 7 to 10 years of market exclusivity plus regulatory incentives. The patient population is concentrated through specialist centres, meaning a small commercial team could realistically reach prescribers if the drug works.

Opthea’s IP runs to 2046 and includes recently filed US patent applications covering VEGF inhibitors for pulmonary and lymphatic disorders. That extends the asset life well beyond the original wet AMD-era patents and matters more in rare disease, where pricing power depends on exclusivity.

We think the orphan economics are the real reason this pivot exists. Wet AMD was a billion-dollar swing-for-the-fences play. LAM is a much smaller market, but one where a working drug at orphan pricing could still support a meaningful valuation.

The Investors Takeaway for Opthea

We first note that shares sunk over 95% when it resumed trading. This shouldn’t be a surprise – investors wanted the tax loss if they didn’t write it off the year before, and it is no longer worth over $700m as it was in March 2026 when it had a drug in 2 Phase 3 trials.

Opthea’s relaunch is honest about what it is (as well as what it is not). The wet AMD failure left scar tissue, and management is not pretending otherwise. Compared to 18 months ago, this company has a smaller board, a stripped budget, a stage-gated program and a clear acknowledgment that the next 18 months are about generating data that will be at an earlier-stage.

What investors should track from here is Stage 1 progress on the nebulised formulation and the preliminary large animal safety data. If those readouts support a move into early human studies, the thesis stays intact. If not, A$13.1 million of spend produces a much harder conversation about whether OPT-302 has a future at all.